HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5-methyl-1-nicotinoyl-2-pyrazoline

Also Known As:

MS 153; MS-153

Networked: 8 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Nicotinic Acids: 13
      - 5-methyl-1-nicotinoyl-2-pyrazoline: 8
- Heterocyclic Acids
  - Nicotinic Acids: 13
    - 5-methyl-1-nicotinoyl-2-pyrazoline: 8

Experts

1.	Sari, Youssef: 2 articles (01/2015 - 01/2014)
2.	Bell, Richard L: 1 article (01/2015)
3.	Engleman, Eric A: 1 article (01/2015)
4.	Rao, P S S: 1 article (01/2015)
5.	Aal-Aaboda, Munaf: 1 article (01/2014)
6.	Alhaddad, Hasan: 1 article (01/2014)
7.	Althobaiti, Yusuf S: 1 article (01/2014)
8.	Boddu, Sai H S: 1 article (01/2014)
9.	Kim, Nathaniel T: 1 article (01/2014)
10.	Leighton, James: 1 article (01/2014)

Related Diseases

1.	Infarction (Infarctions) 04/01/1997 - "Treatment with MS-153 (12.5 mg/kg, i.v. bolus followed by 6.25 mg/kg/hr or 25.0 mg/kg, i.v. bolus followed by 12.5 mg/kg/hr infusion for 7 days) significantly reduced infarct volumes and improved neurological deficits in MCA occluded rats 7 days after occlusion. " 04/01/1997 - "Delayed treatment significantly reduced infarct volume 24 hr after MCA occlusion when MS-153 (25.0 mg/kg, i.v. bolus followed by 12.5 mg/kg/hr infusion for 21 hr) administration was started 3 hr after occlusion. "
2.	Brain Edema (Cerebral Edema) 04/01/1997 - "Brain edema was also significantly improved when MS-153 (25.0 mg/kg, i.v. bolus followed by 12.5 mg/kg/hr infusion for 18 hr) administration was started 6 hr after occlusion."
3.	Cerebral Infarction 09/01/1996 - "In this study we investigated the effects of a novel compound, MS-153 ([R]-[-]-5-methyl-1-nicotinoyl-2-pyrazoline), on elevated brain glutamate concentrations and cerebral infarct volume induced by middle cerebral artery (MCA) occlusion in the rat. " 09/01/1996 - "The reduction in the size of cerebral infarction by MS-153 may be attributable to the inhibition of glutamate release or an increase in cellular glutamate uptake." 09/01/1996 - "At 3.13 mg/kg per hour, MS-153 reduced glutamate concentration (P < .05) and also the size of ischemic cerebral infarction (P < .05). " 04/01/1997 - "MS-153 ((R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline), a glutamate release inhibitor and YM90K [6-(1 H-imidazol-1-yl)-7-nitro-2,3(1H, 4H)-qunoxalinedione monohydrochloride, an alpha-amino-3hydroxy-5methyl-4-isoxazole (AMPA) antagonist reduced the cerebral infarction 24 hr after the MCA occlusion. "
4.	Ischemia 04/01/1997 - "Cerebroprotective effects of a novel pyrazoline derivative, MS-153, on focal ischemia in rats." 12/15/1999 - "Furthermore, the increase in glutamate efflux by ischemia (hypoxia/aglycemia) was partially, but significantly inhibited by MS-153. "
5.	Alcoholism (Alcohol Abuse) 01/01/2014 - "These findings reveal MS-153 as a GLT1 modulator that may have potential as a therapeutic drug for the treatment of alcohol dependence. " 01/01/2015 - "Regarding glutamatergic homeostasis, ceftriaxone, MS-153, and GPI-1046, which upregulate glutamate transporter 1 (GLT1) expression in mesocorticolimbic brain regions, reduce alcohol intake in genetic animal models of alcoholism. "

Related Drugs and Biologics

1.	Glutamic Acid (Glutamate)
2.	Amino Acid Transport System X-AG (Glutamate Transporter)
3.	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
4.	Phencyclidine (Angel Dust)
5.	Naloxone (Narcan)
6.	Morphine (MS Contin)
7.	Ceftriaxone (Ceftriaxon)
8.	GPI 1046
9.	6- (1H- imidazol- 1- yl)- 7- nitro- 2,3(1H,4H)- quinoxalinedione

Related Therapies and Procedures

1.	Treatment Delay